Assessment of cutaneous toxcitiy in cancer patients treated with CDK 4/6 inhibitors and endocrine therapy according to patient-related outcomes at the University Hospital for tumors (CROSBI ID 734137)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Jakšić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović Mavić, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert
engleski
Assessment of cutaneous toxcitiy in cancer patients treated with CDK 4/6 inhibitors and endocrine therapy according to patient-related outcomes at the University Hospital for tumors
Cyclin-dependent kinases 4/6 inhibitors (CDKi), abemaciclib, ribociclib, and palbociclib, along with endocrine therapy are standard of care in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer.This specific therapy improves treatment outcomes for this defined population adjacent to a manageable toxicity profile. This analysis of real-life clinical practice has asserted that cutaneous toxicity is prevalent in this observed population also announced the requirement for enhanced compassion of symptoms experienced by patients on this specific treatment.
CDKi, cutaneous toxicity, rash
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
88-89.
2022.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Libri oncologici : Croatian journal of oncology
0300-8142
2584-3826
Podaci o skupu
15. Hrvatski onkološki kongres
poster
31.03.2022-03.04.2022
Opatija, Hrvatska